Atlas Trials

Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del

Clinical trial NCT02797132 · COMPLETED

Trial details

NCT number
NCT02797132
Sponsor
Vertex Pharmaceuticals Incorporated
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Cystic Fibrosis
Start date
2016-05-01
Primary completion
2017-09-01
Enrollment
62

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.